Whether they would be developed if industry margins go down is a contentious issue. They seem to do just fine despite the competition from generics. In general

Whether they would be developed if industry margins go down is a contentious issue. They seem to do just fine despite the competition from generics. In general everything related to biology seem to suffer from the problem of high cost . There got to be a lot of inefficiency some where to sustain such high cost. It need not necessarily be human inefficiency. Just like computers moved from being as big and costly as big buildings to being very affordable (raspberry pi) - thanks to the invention of transistor, there must be some kind of bottle neck that can be targeted first to advance the whole field. You can't do that by simply throwing more money at it. You have to create incentives to attack the inefficiencies.